By Julie Steenhuysen, Siddhi Mahatole and Mariam Sunny May 1 (Reuters) - Moderna surpassed Wall Street estimates for ...

For FY 2026, the company is targeting up to 10% growth over its 2025 revenue. ・Moderna’s Q1 net product sales rose on ...

A surprising backup system in the immune response to mRNA vaccines may hold the key to more effective cancer treatments.

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...

Biotechnology company Moderna (NASDAQ:MRNA) reported Q1 CY2026 results , with sales up 260% year on year to $389 million. Its ...

ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology ...

A new study by researchers at the Icahn School of Medicine at Mount Sinai overturns a longstanding assumption about how mRNA ...

Myocarditis is recognized as a rare but serious adverse reaction to messenger RNA (mRNA) vaccination against COVID-19.

With the introduction of mRNA vaccines in the 2010s – vaccines that use messenger RNA molecules in cells to train the body to ...

RNA technology is regarded as one of the newest frontiers in medicine, but in fact a primordial innovator got there way ...

The mRNA-based Covid vaccines helped blunt the impact of the pandemic but also sparked political backlash that has threatened ...

A stabilized mRNA carrier turns tumor injection into broader immune activation by extending vaccine delivery to lymph nodes ...